1-8 of 8
Mark A. Lemmon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

Free
Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn H. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Levens, John M. Maris, Ronen Marmorstein, Steven J. Metallo, Julie R. Park, Linda Z. Penn, Michael Rape, Martine F. Roussel, Kevan M. Shokat, William P. Tansey, Kliment A. Verba, Seychelle M. Vos, William A. Weiss, Elmar Wolf, Yaël P. Mossé
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (7): 1627–1632.
https://doi.org/10.1158/0008-5472.CAN-20-3108
Published: 01 April 2021
View articletitled, Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Open the PDF for Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers in another window
Journal Articles

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Available to Purchase
Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg, Dylan Farnsworth, Kristin S. Price, Hina Khan, Kumar Dilip Ashtekar, Mmaserame Gaefele, Deborah Ayeni, Tyler F. Stewart, Alexandra Kuhlmann, Susan M. Kaech, Arun M. Unni, Robert Homer, William W. Lockwood, Franziska Michor, Sarah B. Goldberg, Mark A. Lemmon, Paul D. Smith, Darren A.E. Cross, Katerina Politi
Journal: Cancer Research
Cancer Res (2020) 80 (10): 2017–2030.
https://doi.org/10.1158/0008-5472.CAN-19-3819
Published: 15 May 2020
View articletitled, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Open the PDF for Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract 3904: Overcoming resistance to HER2 inhibitors through cell based screening

Free
Chris J. Novotny, Sirkku Pollari, Jin H. Park, Mark A. Lemmon, Peter G. Schultz, Weijun Shen, Kevan M. Shokat
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3904.
https://doi.org/10.1158/1538-7445.AM2016-3904
Published: 15 July 2016
View articletitled, Abstract 3904: Overcoming resistance to HER2 inhibitors through cell based screening
Journal Articles

Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma

Free
Nicole Infarinato, Jin Park, Renata Sano, Kateryna Krytska, Hannah Ryles, Helen Zou, Nathan Lee, Tod Smeal, Mark A. Lemmon, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1619.
https://doi.org/10.1158/1538-7445.AM2015-1619
Published: 01 August 2015
View articletitled, Abstract 1619: The next-generation ALK inhibitor PF-06463922 overcomes primary resistance to crizotinib in neuroblastoma
Journal Articles

Abstract 1106: Mechanism for activation of mutated EGF receptors in lung cancer.

Free
Monica L. Red Brewer, Darson Lai, Mark A. Lemmon, William Pao
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 1106.
https://doi.org/10.1158/1538-7445.AM2013-1106
Published: 15 April 2013
View articletitled, Abstract 1106: Mechanism for activation of mutated EGF receptors in lung cancer.
Journal Articles

Abstract 4685: Mechanistic guidance of ALK inhibition for the treatment of neuroblastoma

Free
Scott C. Bresler, Andrew Wood, Elizabeth Haglund, James Christensen, John M. Maris, Mark A. Lemmon, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4685.
https://doi.org/10.1158/1538-7445.AM2011-4685
Published: 15 April 2011
View articletitled, Abstract 4685: Mechanistic guidance of ALK inhibition for the treatment of neuroblastoma
Journal Articles

Abstract 4563: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

Free
Erica L. Carpenter, Elizabeth A. Haglund, Adrian K. Chow, Andrew C. Wood, Lili T. Belcastro, James G. Christensen, Marc Vigny, John M. Maris, Mark A. Lemmon, Yael P. Mosse
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4563.
https://doi.org/10.1158/1538-7445.AM2011-4563
Published: 15 April 2011
View articletitled, Abstract 4563: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Journal Articles

Heregulin β1 induces cyclin D1 and p21 expression and promotes breast cancer cell proliferation through ErbB receptor/Rac/Erk

Free
Chengfeng Yang, Ying Liu, Mark A. Lemmon, Marcelo G. Kazanietz
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 627–628.
Published: 15 April 2006
View articletitled, Heregulin β1 induces cyclin D1 and p21 expression and promotes breast cancer cell proliferation through ErbB receptor/Rac/Erk